A Groundbreaking Treatment Offers New Hope for Glioblastoma Patients
A 43-year-old father, Ben Trotman, has made headlines after being cleared of glioblastoma, the most aggressive and deadly form of brain cancer. Diagnosed in October 2022, Mr. Trotman underwent an experimental immunotherapy treatment two years ago, which has now resulted in no signs of the disease. This development marks a significant breakthrough in the fight against a condition that typically claims lives within 12 to 18 months.
Dr. Paul Mulholland, a consultant medical oncologist leading the trial and treating Mr. Trotman, highlighted the rarity of such outcomes. “It is very unusual to have a clear scan with glioblastoma, especially when he didn’t undergo the follow-up surgery that was initially planned,” he said. Despite this, Mr. Trotman’s tumor remains under control, offering hope for long-term remission.
Mr. Trotman married his wife, Emily, just two months after the immunotherapy treatment in 2023, and in April, they welcomed their daughter, Mabel. Reflecting on his journey, he described the diagnosis as the most traumatic experience of his life. “We were grappling with the fact that Ben had gone from being apparently perfectly healthy to having months to live,” he said. He credited Dr. Mulholland and the treatment as a lifeline in an otherwise devastating situation.
After the initial diagnosis, Mr. Trotman underwent standard treatments, including radiotherapy and chemotherapy. He also continues to have quarterly scans, all of which have returned clear results. While the future remains uncertain, the encouraging outcomes have given him and Emily renewed hope. “We are focused on rebuilding the life we thought we had lost and enjoying being parents,” he said.
The trial, conducted at University College London Hospital’s National Hospital for Neurology and Neurosurgery, builds on a previous study involving the same drug, which was halted due to low participation. However, a fundraising campaign led by Dame Siobhain McDonagh MP helped raise over £1 million to support the new trial. This initiative was inspired by her sister, Baroness McDonagh, who died from glioblastoma in 2023.
Dame Siobhain shared how her sister, Margaret, was deeply affected by the lack of progress in brain cancer treatment. “Changing this was Margaret’s final campaign,” she said. “I am so grateful to the many people who knew and respected Margaret who have come together to help raise funds and campaign for this new trial.”
Dr. Mulholland emphasized the importance of the trial, noting that patients will receive immune-boosting treatment before other interventions, when they are in the best condition to tolerate it. “We’re taking everything we have learned from previous trials into this new study and we are already planning follow-on trials,” he said. His goal is to find a cure for glioblastoma, a disease with a grim prognosis.
The National Brain Appeal is currently funding two posts to support Dr. Mulholland’s research. The treatment is being conducted at the NIHR UCLH Clinical Research Facility and the National Hospital for Neurology and Neurosurgery. As the trial progresses, it offers a beacon of hope for patients and families facing one of the most challenging cancers.
